Format

Send to

Choose Destination
Am J Prev Med. 2015 Dec;49(6 Suppl 5):S498-508. doi: 10.1016/j.amepre.2015.08.013.

Post-treatment Neurocognition and Psychosocial Care Among Breast Cancer Survivors.

Author information

1
Division of Cancer Prevention and Control, Epidemiology and Applied Research Branch, CDC, Atlanta, Georgia. Electronic address: nbuchanan@cdc.gov.
2
Northrop Grumman Corporation, Information Systems, Atlanta, Georgia.
3
Division of Cancer Prevention and Control, Epidemiology and Applied Research Branch, CDC, Atlanta, Georgia.
4
Social and Scientific Systems, Inc., Durham, North Carolina.
5
Biostatistics Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.
6
Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina.

Abstract

INTRODUCTION:

Chemotherapy for breast cancer has been associated with cognitive problems; however, the impact of adjuvant hormone therapy is less clear. No studies have explored provider discussions about cognitive concerns or factors associated with neurocognitive treatment. This study examined cognitive problems, factors associated with having a provider discussion, and receipt of neurocognitive treatment.

METHODS:

Female breast cancer survivors (N=2,537) from the Sister Study and the Two Sister Study who were at least 1 year post-treatment were surveyed in 2012 about their cancer therapies (confirmed by medical records); cognitive concerns; related provider discussions; and neurocognitive treatment. A total of 2,296 women were included in the current 2014 analysis. Extensive covariate information was also ascertained for predictive multivariate models.

RESULTS:

The prevalence of self-reported cognitive problems after treatment was 60%. Of those reporting cognitive problems, only 37% had discussed those concerns with a provider and 15% had been treated for cognitive symptoms. The odds of reported cognitive concerns that started during and after treatment were elevated for those who received only hormone therapy and no chemotherapy (OR=1.64, 95% CI=1.15, 2.33); chemotherapy and no hormone therapy (OR=5.63, 95% CI=3.52, 9.00); or both (OR=6.33, 95% CI=4.21, 9.54) compared with those reporting neither treatment.

CONCLUSIONS:

The high prevalence of cognitive concerns underscores the importance of monitoring breast cancer survivors for potential neurocognitive effects of hormone and chemotherapy, discussions with survivors about those concerns, and treatment referrals. Monitoring changes over time can help to evaluate both psychosocial and neurocognitive care provided for survivors.

PMID:
26590645
PMCID:
PMC4656130
DOI:
10.1016/j.amepre.2015.08.013
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center